Kaizen Clinical Services Partners with BioClinica
- CRO Partnership Strengthens Certified eClinical Partner Program -
NEWTOWN, Pa.--(BUSINESS WIRE)-- BioClinica®, Inc., (NASDAQ:BIOC - News), a global provider of clinical trial management services, announced a strategic partnership with Kaizen Clinical Services, Inc., an oncology-focused contract research organization ("CRO").
"Our partnership will enable customers to benefit from Kaizen's expertise in worldwide oncology trials and BioClinica's best-in-class product suite offering," said Peter Benton, President of the eClinical Division of BioClinica. "Kaizen's oncology focus makes it a strong addition to the BioClinica Certified Partner Program, supporting customers in the complex therapeutic areas of study monitoring and management."
The BioClinica Certified Partner ("BCP") Program helps CROs address many of the complexities associated with clinical trials by leveraging the focus and the power of BioClinica software and services. BioClinica solutions enable CROs to start clinical studies more efficiently, optimize data collection, to ensure timely grants payments and track performance. BioClinica solutions provide CROs with the optimal means to more efficiently manage multiple studies with multiple sponsors and to supplement their therapeutic and clinical expertise with BioClinica's global clinical technology support.
Kaizen Clinical Services, based in Jackson, New Jersey, is a woman-owned contract research organization that focuses on oncology trials. Founded in 2007, Kaizen offers project management, clinical monitoring, consulting and training services. The firm has managed and/or monitored Phase I through Phase IV trials that have enrolled between 35 and 2,500 patients. "We are pleased to join BioClinica in this partnership. Kaizen's philosophy is to continually improve our services and performance. This relationship with BioClinica and our access to their extensive suite of services will allow us to maintain our philosophy by enabling us to better serve our clients as well as the oncology investigative community as a whole," said Ernie Stefanelli, President and co-founder of Kaizen Clinical Services, Inc.
Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management, and clinical supply chain forecasting and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.